{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:10:46Z","timestamp":1784632246578,"version":"3.55.0"},"reference-count":102,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T00:00:00Z","timestamp":1536192000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2018.00505","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T04:58:17Z","timestamp":1536209897000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Advances and Unmet Needs in the Therapeutics of Bone Fragility"],"prefix":"10.3389","volume":"9","author":[{"given":"Sabashini K.","family":"Ramchand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ego","family":"Seeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,9,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/206489a0","article-title":"Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling","volume":"206","author":"Hattner","year":"1965","journal-title":"Nature"},{"key":"B2","first-page":"315","article-title":"Skeletal heterogeneity and the purposes of bone remodelling: implications for the understanding of osteoporosis","volume-title":"Osteoporosis","author":"Parfitt","year":"1996"},{"key":"B3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/BF02013227","article-title":"Mean wall thickness of trabecular bone packets in the human iliac crest: changes with age","volume":"26","author":"Lips","year":"1978","journal-title":"Calcif Tissue Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/0221-8747(83)90004-8","article-title":"Histomorphometric analysis of dynamic parameters of trabecular bone formation in the iliac crest of normal British subjects","volume":"5","author":"Vedi","year":"1983","journal-title":"Metab Bone Dis Relat Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S8756-3282(96)00227-X","article-title":"The effects of long-term hormone replacement therapy on bone remodeling in postmenopausal women","volume":"19","author":"Vedi","year":"1996","journal-title":"Bone"},{"key":"B6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s001980050194","article-title":"Bone remodeling and structure in postmenopausal women treated with long-term, high-dose estrogen therapy","volume":"10","author":"Vedi","year":"1999","journal-title":"Osteoporos Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1359\/jbmr.1999.14.7.1217","article-title":"Hormone replacement therapy prevents osteoclastic hyperactivity: a histomorphometric study in early postmenopausal women","volume":"14","author":"Eriksen","year":"1999","journal-title":"J Bone Miner Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/S0140-6736(10)60320-0","article-title":"Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study","volume":"375","author":"Zebaze","year":"2010","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S8756-3282(02)00735-4","article-title":"Misconceptions (2): turnover is always higher in cancellous than in cortical bone","volume":"30","author":"Parfitt","year":"2002","journal-title":"Bone"},{"key":"B10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/0021-9290(88)90186-8","article-title":"Stiffness of compact bone: effects of porosity and density","volume":"21","author":"Schaffler","year":"1988","journal-title":"J Biomech."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures","volume":"17","author":"Johnell","year":"2006","journal-title":"Osteoporos Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/jbmr.2888","article-title":"Addressing the crisis in the treatment of osteoporosis: a path forward","volume":"32","author":"Khosla","year":"2017","journal-title":"J Bone Miner Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/archinte.164.10.1108","article-title":"Bone mineral density thresholds for pharmacological intervention to prevent fractures","volume":"164","author":"Siris","year":"2004","journal-title":"Arch Intern Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.bone.2005.06.004","article-title":"Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective?","volume":"38","author":"Sanders","year":"2006","journal-title":"Bone"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1007\/s00198-006-0135-9","article-title":"The population burden of fractures originates in women with osteopenia, not osteoporosis","volume":"17","author":"Pasco","year":"2006","journal-title":"Osteoporos Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1002\/jbmr.2167","article-title":"Cortical porosity identifies women with osteopenia at increased risk for forearm fractures","volume":"29","author":"Bala","year":"2014","journal-title":"J Bone Miner Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1359\/jbmr.071108","article-title":"Finite element analysis based on in vivo HR-pQCT images of the distal radius is associated with wrist fracture in postmenopausal women","volume":"23","author":"Boutroy","year":"2008","journal-title":"J Bone Miner Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(17)32640-5","article-title":"Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial","volume":"391","author":"Shepstone","year":"2018","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00198-017-4326-3","article-title":"Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study","volume":"29","author":"Rubin","year":"2018","journal-title":"Osteoporos Int."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J Bone Miner Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos Int"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1002\/jbmr.81","article-title":"Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate","volume":"25","author":"Seeman","year":"2010","journal-title":"J Bone Miner Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1359\/JBMR.051109","article-title":"A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide","volume":"21","author":"Lindsay","year":"2006","journal-title":"J Bone Miner Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.bone.2016.11.004","article-title":"Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial","volume":"97","author":"Moreira","year":"2017","journal-title":"Bone"},{"key":"B26","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"B28","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/S2213-8587(17)30188-2","article-title":"Osteoporosis treatment: recent developments and ongoing challenges","volume":"5","author":"Khosla","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/nrendo.2015.71","article-title":"Short-term and long-term effects of osteoporosis therapies","volume":"11","author":"Reid","year":"2015","journal-title":"Nat Rev Endocrinol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1006\/bbrc.1999.1499","article-title":"Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates","volume":"264","author":"van","year":"1999","journal-title":"Biochem Biophys Res Commun."},{"key":"B31","doi-asserted-by":"publisher","first-page":"7829","DOI":"10.1073\/pnas.0601643103","article-title":"The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs","volume":"103","author":"Kavanagh","year":"2006","journal-title":"Proc Natl Acad Sci USA."},{"key":"B32","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1073\/pnas.96.1.133","article-title":"Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro","volume":"96","author":"Fisher","year":"1999","journal-title":"Proc Natl Acad Sci USA."},{"key":"B33","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","article-title":"Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates","volume":"296","author":"Dunford","year":"2001","journal-title":"J Pharmacol Exp Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.bone.2013.11.016","article-title":"Differing effects of denosumab and alendronate on cortical and trabecular bone","volume":"59","author":"Zebaze","year":"2014","journal-title":"Bone"},{"key":"B35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/jbmr.2419","article-title":"Cortical bone: a challenging geography","volume":"30","author":"Zebaze","year":"2015","journal-title":"J Bone Miner Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S8756-3282(02)00923-7","article-title":"Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys","volume":"32","author":"Smith","year":"2003","journal-title":"Bone"},{"key":"B37","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.bone.2010.07.011","article-title":"Greater magnitude of turnover suppression occurs earlier after treatment initiation with risedronate than alendronate","volume":"49","author":"Allen","year":"2011","journal-title":"Bone"},{"key":"B38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00198-006-0274-z","article-title":"Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study","volume":"18","author":"Silverman","year":"2007","journal-title":"Osteoporos Int"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1359\/jbmr.090704","article-title":"Potential mediators of the mortality reduction with zoledronic acid after hip fracture","volume":"25","author":"Colon-Emeric","year":"2010","journal-title":"J Bone Miner Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/jbmr.2442","article-title":"The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"30","author":"Black","year":"2015","journal-title":"J Bone Miner Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1210\/jc.2012-2868","article-title":"Reduction in the risk of clinical fractures after a single dose of zoledronic Acid 5 milligrams","volume":"98","author":"Reid","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"B45","doi-asserted-by":"publisher","first-page":"E1130","DOI":"10.1503\/cmaj.161207","article-title":"Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial","volume":"189","author":"Grey","year":"2017","journal-title":"CMAJ"},{"key":"B46","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/jbmr.2009","article-title":"Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women: a randomized, placebo-controlled trial","volume":"29","author":"Grey","year":"2014","journal-title":"J Bone Miner Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1007\/s00223-018-0418-0","article-title":"Abstracts of the ECTS Congress 2018 - P068 Zoledronate every 18 months for 6 years in osteopenic postmenopausal women reduces non-vertebral fractures and height loss","volume":"102","author":"Reid","year":"2018","journal-title":"Calcif Tissue Int."},{"key":"B48","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1002\/jbmr.149","article-title":"Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies","volume":"25","author":"Reid","year":"2010","journal-title":"J Bone Miner Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates","volume":"101","author":"Miller","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1007\/s00198-014-2692-7","article-title":"Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate","volume":"25","author":"Brown","year":"2014","journal-title":"Osteoporos Int."},{"key":"B52","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","article-title":"Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study","volume":"58","author":"Roux","year":"2014","journal-title":"Bone"},{"key":"B53","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.bone.2011.03.769","article-title":"Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody","volume":"49","author":"Kostenuik","year":"2011","journal-title":"Bone"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/jbmr.2480","article-title":"Sustained modeling-based bone formation during adulthood in cynomolgus monkeys may contribute to continuous BMD gains with denosumab","volume":"30","author":"Ominsky","year":"2015","journal-title":"J Bone Miner Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/jbmr.3309","article-title":"Remodeling- and modeling-based bone formation with teriparatide versus denosumab: a longitudinal analysis from baseline to 3 months in the AVA study","volume":"33","author":"Dempster","year":"2018","journal-title":"J Bone Miner Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1210\/jc.2010-1805","article-title":"Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial","volume":"96","author":"Miller","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"B58","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s00198-015-3459-5","article-title":"Multiple clinical vertebral fractures following denosumab discontinuation","volume":"27","author":"Anastasilakis","year":"2016","journal-title":"Osteoporos Int."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","article-title":"Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports","volume":"27","author":"Aubry-Rozier","year":"2016","journal-title":"Osteoporos Int."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","article-title":"Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics","volume":"27","author":"Popp","year":"2016","journal-title":"Osteoporos Int."},{"key":"B62","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/jc.2017-00096","article-title":"Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report","volume":"102","author":"Lamy","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"key":"B63","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s12020-016-1030-6","article-title":"Clinical vertebral fractures following denosumab discontinuation","volume":"54","author":"Polyzos","year":"2016","journal-title":"Endocrine"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J Bone Miner Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled freedom trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res."},{"key":"B66","first-page":"273","article-title":"Morphological basis of bone mineral measurements: transient and steady state effects of treatment in osteoporosis","volume":"4","author":"Parfitt","year":"1980","journal-title":"Miner Electrolyte Metab."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1359\/jbmr.1997.12.8.1152","article-title":"Exploiting and bypassing the bone remodeling cycle to optimize the treatment of osteoporosis","volume":"12","author":"Dempster","year":"1997","journal-title":"J Bone Miner Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/BF00316875","article-title":"Bone strength: the bottom line","volume":"51","author":"Einhorn","year":"1992","journal-title":"Calcif Tissue Int."},{"key":"B69","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"key":"B70","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/jbmr.2496","article-title":"Co-administration of antiresorptive and anabolic agents: a missed opportunity","volume":"30","author":"Seeman","year":"2015","journal-title":"J Bone Miner Res."},{"key":"B71","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1007\/s00198-013-2341-6","article-title":"An evaluation of the Fracture Risk Assessment Tool (FRAX(R)) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX(R)","volume":"24","author":"Kaufman","year":"2013","journal-title":"Osteoporos Int."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.bone.2006.05.007","article-title":"Raloxifene enhances vertebral mechanical properties independent of bone density","volume":"39","author":"Allen","year":"2006","journal-title":"Bone"},{"key":"B74","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1210\/en.2007-0275","article-title":"Raloxifene enhances material-level mechanical properties of femoral cortical and trabecular bone","volume":"148","author":"Allen","year":"2007","journal-title":"Endocrinology"},{"key":"B75","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.bone.2014.01.009","article-title":"Bone cell-independent benefits of raloxifene on the skeleton: a novel mechanism for improving bone material properties","volume":"61","author":"Gallant","year":"2014","journal-title":"Bone"},{"key":"B76","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00198-015-3354-0","article-title":"Recurrence of bilateral atypical femoral fractures associated with the sequential use of teriparatide and denosumab: a case report","volume":"27","author":"Ramchand","year":"2016","journal-title":"Osteoporos Int"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1359\/jbmr.070413","article-title":"Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis","volume":"22","author":"Chen","year":"2007","journal-title":"J Bone Miner Res"},{"key":"B78","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00223-016-0171-1","article-title":"Six weeks of daily abaloparatide treatment increased vertebral and femoral bone mineral density, microarchitecture and strength in ovariectomized osteopenic rats","volume":"99","author":"Bahar","year":"2016","journal-title":"Calcif Tissue Int."},{"key":"B79","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00198-017-4304-9","article-title":"Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial","volume":"29","author":"Bilezikian","year":"2018","journal-title":"Osteoporos Int."},{"key":"B80","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1210\/jc.2016-1160","article-title":"Effects of two years of teriparatide, denosumab, or both on bone microarchitecture and strength (DATA-HRpQCT study)","volume":"101","author":"Tsai","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"B81","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00198-010-1226-1","article-title":"Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis","volume":"22","author":"Macdonald","year":"2011","journal-title":"Osteoporos Int."},{"key":"B82","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1210\/jc.2014-3718","article-title":"Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis","volume":"100","author":"Leder","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"B83","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/jbmr.3042","article-title":"Abaloparatide is an anabolic, but does it spare resorption?","volume":"32","author":"Martin","year":"2017","journal-title":"J Bone Miner Res."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00198-015-3374-9","article-title":"Bone remodeling markers: so easy to measure, so difficult to interpret","volume":"27","author":"Seeman","year":"2016","journal-title":"Osteoporos Int."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/jbmr.3427","article-title":"FRAME Study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab","volume":"33","author":"Cosman","year":"2018","journal-title":"J Bone Miner Res."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/jbmr.3452","article-title":"Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study","volume":"33","author":"McClung","year":"2018","journal-title":"J Bone Miner Res."},{"key":"B90","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/jbmr.3384","article-title":"Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the VERO trial","volume":"33","author":"Geusens","year":"2018","journal-title":"J Bone Miner Res."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med."},{"key":"B92","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1210\/jc.2006-0190","article-title":"Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men","volume":"91","author":"Finkelstein","year":"2006","journal-title":"J Clin Endocrinol Metab."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N Engl J Med."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMe038143","article-title":"Parathyroid hormone plus alendronate\u2013a combination that does not add up","volume":"349","author":"Khosla","year":"2003","journal-title":"N Engl J Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J Bone Miner Res"},{"key":"B96","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"key":"B97","doi-asserted-by":"publisher","first-page":"4295","DOI":"10.1210\/endo.142.10.8437","article-title":"OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats","volume":"142","author":"Kostenuik","year":"2001","journal-title":"Endocrinology"},{"key":"B98","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1359\/jbmr.060915","article-title":"Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice","volume":"22","author":"Samadfam","year":"2007","journal-title":"J Bone Miner Res."},{"key":"B99","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.bone.2013.01.007","article-title":"A new method of segmentation of compact-appearing, transitional and trabecular compartments and quantification of cortical porosity from high resolution peripheral quantitative computed tomographic images","volume":"54","author":"Zebaze","year":"2013","journal-title":"Bone"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"key":"B101","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2018.00505\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T22:38:48Z","timestamp":1751841528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2018.00505\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,6]]},"references-count":102,"alternative-id":["10.3389\/fendo.2018.00505"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2018.00505","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,6]]},"article-number":"505"}}